Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
58,643,980
-
Number of holders
-
215
-
Total 13F shares, excl. options
-
63,492,585
-
Shares change
-
+1,630,536
-
Total reported value, excl. options
-
$2,545,823,532
-
Value change
-
+$81,769,913
-
Put/Call ratio
-
91%
-
Number of buys
-
105
-
Number of sells
-
-103
-
Price
-
$40.14
Significant Holders of AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO) as of Q3 2025
273 filings reported holding AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock as of Q3 2025.
AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO) has 215 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63,492,585 shares
.
Largest 10 shareholders include FARALLON CAPITAL MANAGEMENT LLC (5,781,066 shares), VANGUARD GROUP INC (5,604,876 shares), BlackRock, Inc. (4,545,738 shares), Bellevue Group AG (3,714,736 shares), Erste Asset Management GmbH (2,764,900 shares), Paradigm Biocapital Advisors LP (2,673,555 shares), WELLINGTON MANAGEMENT GROUP LLP (2,471,416 shares), Commodore Capital LP (2,338,287 shares), STATE STREET CORP (2,262,712 shares), and MACQUARIE GROUP LTD (1,958,101 shares).
This table shows the top 215 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.